Umfrage zur Nutzung unserer Internetseite
Sehr geehrte/r Besucher/in unseres Internetauftrittes,

wir, das Universitätsklinikum Halle (Saale), führen im Moment eine Umfrage über die Nutzung unserer Internetseite durch. Mit den Ergebnissen dieser völlig anonymen und freiwilligen Umfrage wollen wir unsere Seite für Sie attraktiver und besser nutzbar machen. Wir würden uns deshalb sehr über Ihre Teilnahme freuen. Das Beantworten der Fragen dauert auch nur wenige Minuten.

Unsere Datenschutzinformationen finden Sie unter Datenschutzerklärung
Teilnehmen
Ich möchte nicht teilnehmen
Notfälle
Blutspende
Karriere
Presse
Forschung
Lehre
Patienten
Zuweiser

Publikationen (2010-2017)

 

Konrad, H., Wahle, A., Altermann, W. and Schlaf, G.: Strong humoral anti-HLA immune response upon arbitrarily chosen allogeneic arterial vessels. 
J. Clin. Cell. Immunol. 8 (2017); DOI: 10.4172/2155-9899.1000525; Epub 2017 Oct 23rd

 

Goebel, S., Kehlen, A., Bluemke, K., Altermann, W., Schlaf, G., Fischer, K., Fornara, P., Wullich, B., Wach, S and Taubert H.: Differences in the frequencies of HLA-class I and II alleles between German patients with renal cell carcinoma and healthy controls.
Cancer Immunol. Immunother. (2017); DOI 10.1007/s00262-017-1957-3; Epub 2017 Febr 9th

 

Schlaf, G. and Altermann, W.: Basiliximab: Well-established as an immunosuppressive therapeutic antibody, but falsifying the outcome of lymphocytotoxicity-based standard cross-matching.
Buchbeitrag in: Basiliximab: Indications, Contraindications and adverse effects. Editor: Leon V. Berhardt, Chapter 5 / ID 45615 (2017): 96-113, NOVA Science Publishers Inc., New York, USA 

 

Schlaf, G., Rothhoff, A. and Altermann, W.: Der Festphasen-Kreuztest als valides diagnostisches Werkzeug zum Nachweis falsch positiver Kreuztestresultate bei Patienten mit begleitenden Autoimmunerkrankungen [Solid phase-based cross-matching as a valid tool to detect false positive CDC-based crossmatch results in recipients with accompanying autoimmune diseases].
Transfusionsmedizin 6 (2016): 169-173 (DOI 10.1055/s-0042-114209)

 

ELISA-based cross-matching allowing the detection of emerging donor-specific anti-HLA antibodies through the use of stored donors‘ cell lysates; Schlaf G, Stöhr K, Rothhoff A, Altermann W; Case Rep. Transplant.; 2015; 763157; Epub 2015 Oct 15th

 

Detection of post-transplant anti-HLA donor-specific antibodies through the use of stored donors’ cell lysates and solid phase-based cross-matching; Schlaf G, Pistorius I, Altermann W; J. Clin. Cell. Immunol.; 2015; 6; 383-391

 

Solid phase-based cross-matching in order to avoid kidney allografting against donor-specific anti-HLA antibodies: Long term experience with a procedure allowing highly reliable diagnoses; Schlaf G, Pollok-Kopp B, Altermann W; Austin J. Nephrol. Hypertens.; 2014, 1(6); Epub November 2014, Printversion folgt

 

Solid phase-based cross-matching as solution for kidney allograft recipients pretreated with therapeutic antibodies; Schlaf G, Apel S, Wahle A, Altermann W; BioMed Res. Int.; 2014; Epub September 2014, Printversion folgt

 

Systemic Lupus Erythematosus leading to terminal renal failure and excluding patients from kidney allocation due to inadequate CDC-based cross-matching: Is there a way out?; Schlaf G, Rothhoff A, Altermann W; J. Clin. Cell. Immunol.; 2014; Epub März 2014, Printversion folgt

 

Sensitive solid-phase detection of donor-specific antibodies as an aid highly relevant to improving allograft outcomes; Schlaf G, Pollok-Kopp B, Altermann W; Mol. Diagn. Ther.; 2014, 18, 185

Individual composition of human leukocyte antigens and periodontopathogens in the background of periodontitis; Reichert S, Altermann W, Stein JM, Schaller HG, Machulla HK, Schulz S; J Periodontol.; 2013, 84, 100

Artificially positive crossmatches not leading to the refusal of kidney donations due to the usage of adequate diagnostic tools; Schlaf G, Pollok-Kopp B, Schabel E, Altermann W; Case Rep. Transplant.; Epub April 2013, Printversion folgt

Buchbeitrag: „Improved detection of donor-specific anti-HLA antibodies and increased reliability of pre- and post-transplant cross-matching relevant for organ allograft survival through the use of novel solid phase-based assays” Schlaf G, Pollok-Kopp B, Altermann W als Kapitel für das Buch “Organ Donation and Organ Donors: Issues, Challenges and Perspectives”; Editor Reza F. Saidi, Nova Science Publishers, Inc., New York, USA; Buchedition im Jahr 2013

Hodgkin’s lymphoma RNA-transfected dendritic cells induce cancer/testis antigen-specific immune responses; Winkler C, Steingrube DS, Altermann W, Schlaf G, Max D, Kewitz S, Emmer A, Kornhuber M, Banning-Eichenseer U, Staege MS; Cancer Immunol. Immunother. 2012, 61, 1769

General isufficiency of the classical CDC-based crossmatch to detect donor-specific anti-HLA antibodies leading to invalid results under recipients’ medical treatment or underlying diseases; Schlaf G, Mauz-Körholz C, Ott U, Leike S, Altermann W; Histol. Histopathol.; 2012, 27, 31

Generation of donor-specific anti-HLA antibodies after the transplantation of a fully-matched kidney allograft. Impact on the selection of a subsequent renal regraft: A case report; Schlaf G, Radam C, Wahle A, Altermann W; Transplant. Proc.; 2012, 381, 23 A novel ELISA-based crossmatch procedure to detect donor-specific anti-HLA antibodies responsible for corneal allograft rejections; Sel S/Schlaf G, Schurat O, Altermann W; J. Immunol. Methods; 2012, 381, 23 

Novel solid phase-based ELISA assays contribute to an improved detection of anti-HLA antibodies and to an increased reliability of pre- and post-transplant crossmatching; Schlaf G, Pollok-Kopp B, Manzke T, Schurat O, Altermann W; Nephrol. Dial. Transplant. PLUS; 2010, 3, 527

HLA-Labor

Leitung:
Dr. med. W. Altermann
PD Dr. rer. nat. G. Schlaf

Annahme & HLA-Typisierung
Telefon: (0345) 557-1456 

anti-HLA Antikörper-Diagnostik
Telefon: (0345) 557-1456
Telefax: (0345) 557-1849

Standort:
Ernst-Grube-Straße 40, Komplement, 3. Ebene